Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.45 |
| ▸ | EGFR | P00533 | 5/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334890 | 0.92 | NPC1 (0.47) | NPC1SIGMAR1EGFRERBB2GLS | |
| SCHEMBL334404 | 0.92 | NPC1 (0.47) | NPC1SIGMAR1EGFRERBB2GLS | |
| SCHEMBL335312 | 0.84 | AIMP2 (0.49) | NPC1SIGMAR1EGFRERBB2GLS | |
| SCHEMBL334813 | 0.80 | L3MBTL1 (0.59) | NPC1SIGMAR1GAAHPGDALDH1A1 | |
| SCHEMBL335818 | 0.78 | MAPT (0.50) | EGFRERBB2GAAALDH1A1 | |
| SCHEMBL335234 | 0.77 | NPC1 (0.53) | NPC1ALDH1A1 | |
| SCHEMBL334661 | 0.76 | LMNA (0.61) | NPC1SIGMAR1GAAHPGDALDH1A1 | |
| SCHEMBL334538 | 0.76 | L3MBTL1 (0.55) | EGFRERBB2HPGD | |
| SCHEMBL334352 | 0.75 | LMNA (0.63) | NPC1SIGMAR1HPGDALDH1A1 | |
| SCHEMBL335982 | 0.73 | DGAT2 (0.37) | GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | NPC1 209/4885SIGMAR1 3998/4885EGFR 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.